wbldb
home
|
authors
|
theses
Ott, Susan M.
1
Consider the bisphosphonate dose
J Bone Miner Res
. 2022;37(1):1-2
©2021 American Society for Bone and Mineral Research
Affiliations
1
Department of Medicine,
University of Washington
, Seattle, WA, USA
Links
DOI:
10.1002/jbmr.4479
PubMed:
34841571
WoS:
000729782400001
History
Received: 2021-11-06
Accepted: 20-11-20
Cited Works (12)
Year
Entry
2001
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group.
NEJM
. February 1, 2001;344(5):333-340.
1990
Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
NEJM
. March 22, 1990;322(12):802-809.
2007
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
NEJM
. May 3, 2007;356(18):1809-1822.
2017
Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.
Proc Natl Acad Sci USA
. August 15, 2017;114(33):8722-8727.
2012
Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM. Incidence of atypical nontraumatic diaphyseal fractures of the femur.
J Bone Miner Res
. December 2012;27(12):2544-2550.
1995
Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB; Group, Alendronate Phase III Osteoporosis Treatment Study. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.
NEJM
. November 30, 1995;333(22):1437-1443.
1996
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Lancet
. December 7, 1996;348(9041):1535-1541.
1997
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
J Clin Invest
. September 15, 1997;100(6):1475-1480.
2002
Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion: the Parfitt view.
J Bone Miner Res
. August 2002;17(8):1558-1559.
2002
Parfitt AM. Misconceptions (2): turnover is always higher in cancellous than in cortical bone.
Bone
. June 2002;30(6):807-809.
2012
Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.
J Bone Miner Res
. April 2012;27(4):825-834.
2012
Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.
J Bone Miner Res
. March 2012;27(3):672-678.